Growth, tolerability and reports
MD Sermorelin: growth and side effects
The childhood growth findings deserve their own space. So do the irritation, metabolic measurements and adult accounts that complicate an easy story about benefits.
Sermorelin for children
The most concrete reason to discuss sermorelin to grow taller comes from children with growth hormone deficiency. In the multicenter first-year growth trial, height velocity rose from about 4.1 cm/year to roughly 7-8 cm/year, without excessive IGF-1 generation. Height velocity means the rate of growth over time.
This is the specificity I admire: a defined childhood condition, a measured change and a stated observation period. The pediatric review by Prakash and Goa describes sermorelin’s diagnostic and treatment roles in idiopathic GH deficiency. Extending that history to everyone who hopes to gain height would require evidence for those other circumstances.
The historical study doses retain the treatment context. A child’s diagnosis, response and safety assessment cannot be reconstructed from a dose value alone.
IGF-1 and sermorelin
GH prompts production of IGF-1, largely in the liver; IGF-1 carries many downstream growth effects and feeds back on GH secretion. In the short study in older men, 14 days of GHRH(1-29) raised GH and IGF-1 toward the values seen in younger men. That demonstrates a hormone response.
I’m unconvinced by talk that promotes a younger hormone profile into a younger person. The Vittone study in 11 older men is a useful complication: over 6 weeks, nocturnal GH release and measured upper-body strength increased, while IGF-1 failed to reach statistical significance and DEXA body-composition measurements remained unchanged. Different measurements were telling different parts of the story.
Access, on the record
Nothing above is a protocol
Everything on this page is either a trial result or a self-report, and neither one is a schedule anybody is accountable for. For U.S. patient care, sermorelin requires a clinician's prescription for a compounded preparation without FDA approval; the published trials cannot stand in for that decision.
Telehealth provides one setting for this individual prescribing decision. At mypromise.com, Promise Peptides prescribes sermorelin in prescription-only care for U.S. patients; its licensed U.S. clinicians assess each case, and some requests end in a refusal. The patient's state and the treatment being considered determine which options can be offered. Naming the route is not a recommendation to take it — it is the answer to the question this page cannot answer, which is who decides.
Antibodies and irritation
The Chen childhood study reported mild injection-site irritation in three children and no serious side effects. Its antibody result—the one that starts this site—was striking: nearly all participants developed GHRH antibodies, without a correlation with growth. The longer Lanes and Carrillo follow-up also found antibodies in some responders without apparent interference with growth.
For me, those observations argue for asking what a detected antibody actually did. They support neither panic at every positive assay nor an assurance that repeated adult exposure has been fully settled.
In older adults receiving [Nle27]GHRH(1-29)-NH2 for 16 weeks, Khorram and colleagues reported transient hyperlipidemia, a rise in blood lipids that resolved by the study’s end. Blood pressure and body weight were unchanged.
Adverse events with tesamorelin
The Baker trial’s safety findings concern tesamorelin, a related GHRH analog. Among 137 completers, adverse events were reported in 68% of the active-treatment group and 36% of the placebo group. Most were mild injection-site reactions and joint pain; 17% of treated participants required a dose adjustment. No serious cardiovascular events were reported over the 20-week trial.
That placebo comparison gives the tolerability discussion some substance. I’m judging tesamorelin observations here; an adult sermorelin safety estimate needs its own data.
Glucose tolerance and chronic exposure
A study of PEG-conjugated GHRH found some impairment of glucose tolerance in elderly participants with repeated exposure. Local reactions were more frequent than with placebo, though mild and transient; no GHRH antibodies were observed. This was another formulation, with different exposure characteristics.
Because GH and IGF-1 promote cell growth, chronically raising them carries a theoretical cancer-related concern. The review of GHRH biology and disease provides the broader context. Long-term human data have yet to resolve that concern for adult sermorelin use. Preserved hormonal feedback offers a mechanistic rationale; it cannot supply the missing years of observation.
Product quality adds another uncertainty. The sports-medicine and doping review describes mislabeling and contamination in an inadequately regulated peptide supply chain, while a review of approved and unapproved therapies emphasizes scarce rigorous human safety data for unapproved uses.
Community accounts
Sleep comes up repeatedly in peptide forums and wellness write-ups: deeper rest, vivid dreams, steadier daytime energy and a sense of faster recovery. Other accounts describe gradual fat loss, better muscle tone, firmer-feeling skin or a general lift in well-being. There are also people who notice very little.
These are anecdotal accounts, not clinical evidence. Diet, exercise, expectations and other changes travel with them. My question about these sleep accounts concerns the limited controlled findings, which the sleep question discusses.
The adverse accounts cover redness, itching, swelling or welts at the injection site; headache, flushing, dizziness and nausea; puffiness, hunger and grogginess. Less commonly, people describe tingling fingers or higher blood sugar. Those descriptions identify concerns people experience. They establish neither frequencies nor causes.
Sermorelin overdose
The historical trials provide no individual overdose threshold. Sermorelin’s feedback-regulated mechanism helps explain GH secretion, but it supplies no warrant for calling an excessive exposure harmless. A prescriber or an urgent medical service can assess an actual dosing error.
I reject the reassurance smuggled into calling feedback an insurance policy. It is a biological feature that still leaves questions about the preparation, exposure and person receiving it.
Sermorelin in Henderson
An individual assessment is central to prescription care in Henderson, as elsewhere in the U.S. A licensed clinician decides whether the case warrants a prescription, and may decline it; available options depend on state and treatment. The current preparation is compounded and has no FDA approval.
The studies discussed here cannot assess a particular local practice. The approval and compounding history explains the regulatory setting in which those individual decisions occur.